A Phase 1/2 interventional study of Ibrutinib and DA-EPOCH-R in Diffuse Large B Cell Lymphoma Relapsed and Diffuse Large B Cell Lymphoma Refractory, sponsored by Pharmacyclics LLC.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-05.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing ibrutinib in Lymphoma — 2 open to participants now, 4 under way, none of them phase 3. ibrutinib · Lymphoma.
Among the 19 studies testing ibrutinib in Lymphoma, this one is the 13th largest by enrollment, is one of 3 that started in 2014, is one of 5 in phase 1/2, and was the 8th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →2 of the 19 studies testing ibrutinib in Lymphoma are open now, in 1 country. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Chinese Academy of Medical Sciences
Ages 18–80
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 11 · Phase 3 5
First in 2009; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 80 across the 19 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
15 studies in Lymphoma by AbbVie: none open now, none under way, none of them phase 3. Of 13 finished, 6 (46%) have results posted.
Among the 15 studies in Lymphoma by AbbVie, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2014, is one of 3 in phase 1/2, and was the 11th registered.
AbbVie’s Lymphoma studies by the year they started, since 2004.
2 of the studies testing ibrutinib in Lymphoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02436707Canadian Cancer Trials GroupNovel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | 2026-12-31 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies testing ibrutinib in Lymphoma, from their registry updates:
Among AbbVie’s 15 in Lymphoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL).
This is a Phase 1b, open-label, non-randomized multicenter study conducted in 2 parts. Part 1, will determine the MTD of the combination of ibrutinib, lenalidomide and DA-EPOCH-R in subjects with DLBCL.
Ibrutinib will be administered at a fixed dose of 560 mg and lenalidomide will be dose-escalated. DA-EPOCH-R will be given at standard doses.
For Part 2, the MTD determined in Part 1 will be the dose used for all subjects. If no MTD is identified, then subjects in Part 2 will be treated with the maximum administered doses (MAD, treatment doses from dose Level 4).
The primary objective for Part 2 is to determine the ORR of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with ABC DLBCL as analyzed by gene expression profiling when treated at recommended phase 2 dose (RP2D).
Major inclusion criteria:
Adequate hepatic and renal function:
Adequate hematologic function:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ibrutinib 560 mg PO + DA-EPOCH-R
Drug: Ibrutinib · Drug: DA-EPOCH-R
Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R
Drug: Ibrutinib · Drug: DA-EPOCH-R · Drug: Lenalidomide
Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R
Drug: Ibrutinib · Drug: DA-EPOCH-R · Drug: Lenalidomide
Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
Drug: Ibrutinib · Drug: DA-EPOCH-R · Drug: Lenalidomide
Recommended Phase 2 Dose(RP2D): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
Drug: Ibrutinib · Drug: DA-EPOCH-R · Drug: Lenalidomide
Ibrutinib
Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
Lenalidomide
Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability
Part-1: To determine the maximum tolerated dose (MTD) of the combination of ibrutinib and lenalidomide with dose adjusted EPOCH-R
Time frame: 1 year after last subjects received the first dose
Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy-ORR
Part 2 - Overall Response rate will be defined as the proportion of subjects who achieve either a Complete Response or a Partial Response according to the international Working Group Response Criteria for NHL as assessed by investigator.
Time frame: 1 year after last subjects received the first dose
Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy
Part-1: Overall Response rate (ORR) will defined as the proportion of subjects who achieve either a CR or a PR according to the international Working Group Response Criteria for NHL as assessed by investigator.
Time frame: 1 year after last subjects received the first dose
Number of Subjects With Adverse Events as a Measure of Safety and Tolerability
Part 2: The frequency (number and percentage) of treatment-emergent adverse events will be reported.
Time frame: 1 year after last subjects received the first dose
Progression Free Survival (PFS) and Overall Survival (OS) as a Measure of Efficacy
Part 2: PFS will be measured as time from first study drug administration to disease progression or death from any cause. OS will be measured from the time of first study drug administration until the date of death using Kaplan-Meier methodology.
Time frame: From initial dose date until the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 1 year after the last subject received the first dose, up to 36 months at the most.
Duration of Response (DOR)
Part 2: DOR will be measured from the time by which the measurement criteria are met for CR or PR until the first date by which recurrent or progressive disease is objectively documented.
Time frame: From initial response date until the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 1 year after the last subject received the first dose.
| Milestone | Part 1: Dose Level 1 | Part 1: Dose Level 2 | Part 1: Dose Level 3 | Part 1: Dose Level 4 | Part 2: RP2D |
|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 6 | 20 |
| Completed | 3 | 3 | 3 | 6 | 20 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Part-1: To determine the maximum tolerated dose (MTD) of the combination of ibrutinib and lenalidomide with dose adjusted EPOCH-R
| Participants | Part 1: Dose Level 1 | Part 1: Dose Level 2 | Part 1: Dose Level 3 | Part 1: Dose Level 4 | Part 1: All Treated |
|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability | 0 | 0 | 0 | 1 | 1 |
Part 2 - Overall Response rate will be defined as the proportion of subjects who achieve either a Complete Response or a Partial Response according to the international Working Group Response Criteria for NHL as assessed by investigator.
| Participants | All Subjects Treated at RP2D | ABC Subjects Treated at RP2D |
|---|---|---|
| Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy-ORR | 16 | 9 |
Part-1: Overall Response rate (ORR) will defined as the proportion of subjects who achieve either a CR or a PR according to the international Working Group Response Criteria for NHL as assessed by investigator.
| Participants | Part 1: Dose Level 1 | Part 1: Dose Level 2 | Part 1: Dose Level 3 | Part 1: Dose Level 4 | Part 1: All Treated |
|---|---|---|---|---|---|
| Number of Participants With Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy | 1 | 2 | 0 | 3 | 6 |
Part 2: The frequency (number and percentage) of treatment-emergent adverse events will be reported.
| Participants | All Subjects Treated at RP2D | ABC Subjects Treated at RP2D |
|---|---|---|
| Number of Subjects With Adverse Events as a Measure of Safety and Tolerability | 26 | 14 |
Part 2: PFS will be measured as time from first study drug administration to disease progression or death from any cause. OS will be measured from the time of first study drug administration until the date of death using Kaplan-Meier methodology.
| Months | All Subjects Treated at RP2D | ABC Subjects Treated at RP2D |
|---|---|---|
| Progression Free Survival (PFS) | 4.86 (0.03 to 12.45) | 4.86 (0.03 to 9.69) |
| Overall Survival (OS) | 15.84 (0.26 to 28.22) | 15.84 (0.26 to 28.22) |
Part 2: DOR will be measured from the time by which the measurement criteria are met for CR or PR until the first date by which recurrent or progressive disease is objectively documented.
| Months | All Subjects Treated at RP2D Who Achieved Overall Response | ABC Subjects Treated at RP2D Who Achieved Overall Response |
|---|---|---|
| Duration of Response (DOR) | 3.94 (0.03 to 10.48) | 4.09 (0.03 to 7.69) |
Collected over 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Dose Level 1 | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Part 1: Dose Level 2 | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Part 1: Dose Level 3 | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Part 1: Dose Level 4 | 5/6 (83.3%) | 5/6 (83.3%) | 6/6 (100%) |
| All Subjects Treated at RP2D | 3/26 (11.5%) | 19/26 (73.1%) | 26/26 (100%) |
| Event | Part 1: Dose Level 1 | Part 1: Dose Level 2 | Part 1: Dose Level 3 | Part 1: Dose Level 4 | All Subjects Treated at RP2D |
|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/3 | 1/3 | 1/3 | 0/6 | 6/26 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/3 | 1/3 | 2/6 | 2/26 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/3 | 0/3 | 1/3 | 0/6 | 1/26 |
| Atrial fibrillationCardiac disorders | 0/3 | 1/3 | 1/3 | 0/6 | 1/26 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 0/6 | 0/26 |
| VomitingGastrointestinal disorders | 1/3 | 0/3 | 0/3 | 0/6 | 1/26 |
| DeathGeneral disorders | 1/3 | 0/3 | 0/3 | 0/6 | 0/26 |
| PneumoniaInfections and infestations | 0/3 | 1/3 | 0/3 | 0/6 | 2/26 |
| Pneumococcal sepsisInfections and infestations | 0/3 | 1/3 | 0/3 | 0/6 | 0/26 |
| Septic shockInfections and infestations | 1/3 | 0/3 | 0/3 | 0/6 | 0/26 |
| Event | Part 1: Dose Level 1 | Part 1: Dose Level 2 | Part 1: Dose Level 3 | Part 1: Dose Level 4 | All Subjects Treated at RP2D |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 3/3 | 3/3 | 2/3 | 4/6 | 12/26 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/3 | 1/3 | 1/3 | 3/6 | 12/26 |
| Sinus tachycardiaCardiac disorders | 0/3 | 3/3 | 1/3 | 3/6 | 6/26 |
| NauseaGastrointestinal disorders | 1/3 | 3/3 | 1/3 | 5/6 | 12/26 |
| ConstipationGastrointestinal disorders | 1/3 | 3/3 | 2/3 | 3/6 | 11/26 |
| FatigueGeneral disorders | 2/3 | 3/3 | 1/3 | 5/6 | 13/26 |
| Oedema peripheralGeneral disorders | 1/3 | 3/3 | 3/3 | 2/6 | 7/26 |
| DizzinessNervous system disorders | 1/3 | 3/3 | 2/3 | 3/6 | 8/26 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 3/3 | 0/3 | 1/6 | 1/26 |
| HypotensionVascular disorders | 0/3 | 3/3 | 1/3 | 3/6 | 6/26 |
| Age, Categorical(Participants) | Part 1: Dose Level 1 | Part 1: Dose Level 2 | Part 1: Dose Level 3 | Part 1: Dose Level 4 | Part 2: RP2D | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 3 | 1 | 6 | 11 | 22 |
| >=65 years | 2 | 0 | 2 | 0 | 9 | 13 |
| Age, Continuous(years) | Part 1: Dose Level 1 | Part 1: Dose Level 2 | Part 1: Dose Level 3 | Part 1: Dose Level 4 | Part 2: RP2D | Total |
|---|---|---|---|---|---|---|
| Median | 69 (54 to 89) | 58 (41 to 61) | 67 (58 to 68) | 55 (38 to 61) | 59 (28 to 79) | 58 (28 to 89) |
| Sex: Female, Male(Participants) | Part 1: Dose Level 1 | Part 1: Dose Level 2 | Part 1: Dose Level 3 | Part 1: Dose Level 4 | Part 2: RP2D | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 1 | 0 | 1 | 7 | 9 |
| Male | 3 | 2 | 3 | 5 | 13 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Dose Level 1 | Part 1: Dose Level 2 | Part 1: Dose Level 3 | Part 1: Dose Level 4 | Part 2: RP2D | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 3 | 3 | 6 | 17 | 32 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 3 | 3 |
| Race (NIH/OMB)(Participants) | Part 1: Dose Level 1 | Part 1: Dose Level 2 | Part 1: Dose Level 3 | Part 1: Dose Level 4 | Part 2: RP2D | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 2 | 2 |
| White | 3 | 2 | 3 | 6 | 15 | 29 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 2 | 2 |
| Region of Enrollment(participants) | Part 1: Dose Level 1 | Part 1: Dose Level 2 | Part 1: Dose Level 3 | Part 1: Dose Level 4 | Part 2: RP2D | Total |
|---|---|---|---|---|---|---|
| United States | 3 | 3 | 3 | 6 | 20 | 35 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of May 2014, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2019, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibrutinib